Morphiex Biotherapeutics | Morphiex to Participate in the 4th Annual Chardan Genetic Medicines Conference
602
post-template-default,single,single-post,postid-602,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-content-sidebar-responsive,qode-theme-ver-13.8,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom

Morphiex to Participate in the 4th Annual Chardan Genetic Medicines Conference

Morphiex Biotherapeutics, a company developing the next generation of CD47 therapeutics for cancer, will participate in the 4th Annual Chardan Genetic Medicines Conference. Our CEO, Dr. Schwartz will be presenting a corporate overview of Morphiex and how its lead asset, MBT-001 is differentiated from competing CD47 programs.

  • Chardan Virtual 4th Annual Genetic Medicines Conference
    Tuesday, October 6, 11:30-11:55 AM EDT

More information can be found on Chardan’s website:

https://www.chardan.com/events/X0VFThAAACQAFh-3

Forward-Looking Statements:

Statements made about Morphiex, other than statements of historical fact, reflect the company’s beliefs and assumptions founded on currently available data and information. Statements of Morphiex’s progress, results, timing of preclinical and clinical trials, and projections for product pipelines are examples of forward-looking statements and are based only on current information, assumptions, and expectations that by definition involve risks, uncertainties, and are subject to factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of preclinical studies; clinical trials; research and development programs; regulatory approval processes for clinical trials; competitive technologies and products; patents, engagement and/or termination of corporate and other strategic partnerships and the need for additional funding or financing.

The information contained in this presentation does not purport to be all-inclusive or to contain all of the information that prospective investors may desire. In all cases, interested parties should conduct their own investigation and analysis of Morphiex’ business. No representation or warranty is made as to the accuracy or completeness of these materials, and the only representations or warranties that will be made in connection with any further investment will be the representations and warranties, as may be set forth in the definitive documentation executed by a duly authorized representative of Morphiex.

Tags:


Location

240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com

Social Media

Twitter Facebook LinkedIn